Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
patients with pulmonary hypertension to determine the recommended dose range, evaluate the
change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone
methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung
disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO
Group V PH following 16 weeks of study participation.